Irena Konstantinova - Inventiva Head of Fibrosis Research
| IVEVF Stock | USD 3.64 0.00 0.00% |
Executive
Dr. Irena Konstantinova serves as Head of Fibrosis Research at Inventiva S.A. She has indepth expertise in cell signaling mechanisms and preclinical models of various fibrotic indications, respiratory diseases and diabetes. Before joining Inventiva, she worked for Novartis UK where she managed a team for target identification and drug discovery of NCE and NBE, mainly in the field of idiopathic pulmonary fibrosis and pulmonary arterial hypertension. She is an author of several patents and high impact journal publications including Nature, Cell and Developmental Cell. She pursued her Ph.D. in Molecular Medicine at the Max Planck Institute for Cell Biology and Genetics in Germany.
| Phone | 33 3 80 44 75 00 |
| Web | https://www.inventivapharma.com |
Inventiva Management Efficiency
The company has return on total asset (ROA) of (0.3438) % which means that it has lost $0.3438 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7073) %, meaning that it generated substantial loss on money invested by shareholders. Inventiva's management efficiency ratios could be used to measure how well Inventiva manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Venkatesh Nathamuni | Jacobs Solutions | N/A | |
| Jarrod CPA | Celsius Holdings | 43 | |
| Robert Duff | Jacobs Solutions | 65 | |
| Hih Kim | Primo Brands | N/A | |
| Yolanda Goettsch | Vita Coco | N/A | |
| Robin Lybeck | Celsius Holdings | N/A | |
| Robert Austin | Primo Brands | N/A | |
| Paul Wiseman | Celsius Holdings | N/A | |
| Edwin NegronCarballo | Celsius Holdings | 62 | |
| Brian Franz | Diageo PLC ADR | 53 | |
| David Hass | Primo Brands | 45 | |
| Sally Grimes | Diageo PLC ADR | 53 | |
| Danielle Babich | Celsius Holdings | N/A | |
| Thomas Shropshire | Diageo PLC ADR | N/A | |
| Syl Saller | Diageo PLC ADR | 60 | |
| Corey Baker | Vita Coco | 52 | |
| Shelette Gustafson | Jacobs Solutions | 59 | |
| Paul Storey | Celsius Holdings | 55 | |
| Brant Burchfield | Celsius Holdings | N/A | |
| Nancy Sotomayor | Primo Brands | N/A | |
| Stephen Arnette | Jacobs Solutions | 56 | |
Management Performance
| Return On Equity | -0.71 | |||
| Return On Asset | -0.34 |
Inventiva SA Leadership Team
Elected by the shareholders, the Inventiva's board of directors comprises two types of representatives: Inventiva inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inventiva. The board's role is to monitor Inventiva's management team and ensure that shareholders' interests are well served. Inventiva's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inventiva's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean Volatier, Chief Officer | ||
| Eric LLM, G Counsel | ||
| Frederic Cren, CEO, Co-Founder | ||
| JeanPaul MD, Head Pharmacovigilance | ||
| Michael Cooreman, Chief Officer | ||
| Pierre Broqua, Co-Founder, Chief Scientific Officer | ||
| Irena Konstantinova, Head of Fibrosis Research | ||
| Nathalie Harroy, Head of Human Resources |
Inventiva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Inventiva a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.71 | |||
| Return On Asset | -0.34 | |||
| Operating Margin | (6.37) % | |||
| Current Valuation | 108.8 M | |||
| Shares Outstanding | 42.13 M | |||
| Shares Owned By Insiders | 25.11 % | |||
| Shares Owned By Institutions | 46.96 % | |||
| Price To Book | 2.85 X | |||
| Price To Sales | 21.40 X | |||
| Revenue | 4.19 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Inventiva Pink Sheet
When determining whether Inventiva SA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inventiva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inventiva Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inventiva Sa Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inventiva SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.